The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
Table: Treatments Considered for COVID-19 (online only)
Download PDF:   US English
Med Lett Drugs Ther. 2020 Apr 6;62(1595):e1-289
Disclosures
Principal Faculty
  • Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
  • Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
  • F. Peter Swanson, M.D., Consulting Editor: no disclosure or potential conflict of interest to report
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Discuss the role of available and investigational drugs in the management of COVID-19.
 Select a term to see related articles  ACE inhibitors   Acetaminophen   Actemra   Advil   Anakinra   Angiotensin receptor blockers   antiretrovirals   ARBs   Atazanavir   Avigan   Azithromycin   baricitinib   Chloroquine   cobicistat   Coronavirus   corticosteroids   COVID-19   darunavir   favipravir   HIV   Hydroxychloroquine   Ibuprofen   influenza   Ivermectin   Jakafi   Kaletra   Kevzara   Kineret   Lopinavir   melatonin   Motrin   NSAIDs   Olumiant   Oseltamivir   Plaquenil   Prezcobix   remdesivir   Reyataz   Ribavirin   Ritonavir   ruxolitinib   sarilumab   Stromectol   Tocilizumab   Tylenol   vaccines   Zinc   Zithromax 
Archived; last update: April 1, 2022

View the Table: Treatments Considered for COVID-19

Download PDF: US English

© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.
arrow to previous article
arrow to next article